Search Results
Your search for ,NOt matches 22378 pages
Showing 151 - 200Extended-Interval Dosing of Tarlatamab Found Safe, Effective in SCLC
Extended-interval dosing of intravenous tarlatamab, at 20 mg every 3 weeks or 30 mg every 4 weeks, demonstrated efficacy and safety that was consistent with the approved tarlatamab dosing regimen in patients with small cell lung cancer (SCLC), according to findings from the phase II DeLLphi-309...
Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer
Early-onset colorectal cancer appears to share much of its genomic landscape with average-onset colorectal cancer, although certain molecular alterations may be enriched among younger patients, according to findings reported by Shin et al in JCO Precision Oncology. The investigators examined...
FDA Approves Topical Photodynamic Therapy for Superficial BCC
Today, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for aminolevulinic acid hydrochloride topical gel, 10% (Ameluz), in combination with photodynamic therapy (PDT) using the BF-RhodoLED lamp series, for the treatment of superficial basal cell carcinoma...
Perioperative Atezolizumab Plus Chemotherapy Improves Outcomes in Resectable Stage II–IIIB NSCLC
Patients with resectable stage IIB–IIIB non–small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone. However, these results did ...
What Constitutes Clinical Expertise in an AI-Enabled Era?
In a keynote speech delivered recently at Cleveland Clinic's A.I. Summit for Healthcare Professionals, Peter Clardy, MD, of Google for Health, made the case that the rapid evolution currently underway in AI is unfolding as clinicians are also being asked to make decisions from an ever-expanding...
20th Annual Award for Leadership in Personalized Medicine
The Personalized Medicine Coalition (PMC), a nonprofit organization dedicated to advancing personalized medicine, recently announced that physician-scientist Norman E. “Ned” Sharpless, MD, has been selected as the recipient of the 20th Annual Award for Leadership in Personalized Medicine,...
Envafolimab Regimen Improves Pathologic Complete Response in MSS Locally Advanced Rectal Cancer
Adding the subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX (capecitabine and oxaliplatin) improved pathologic complete response (pCR) without a clear safety or surgical feasibility penalty in patients with microsatellite-stable (MSS) locally advanced rectal cancer,...
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) recently approved daraxonrasib, (Rasonque), a multiselective RAS(ON) inhibitor, for treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. ...
Structured Exercise After Adjuvant Chemotherapy for Colon Cancer Improves Survival and Saves Costs
A structured exercise program after adjuvant chemotherapy for colon cancer improved survival and saved money. In a preplanned cost-utility analysis of the phase III CHALLENGE trial, presented at the 2026 ASCO Annual Meeting1 and published simultaneously in the Journal of Clinical Oncology,2 the...
Long-Term Trial Supports Selective Use of Extended Pelvic Lymph Node Dissection in High-Grade Prostate Cancer
Extended pelvic lymph node dissection has long been used during radical prostatectomy to improve staging in men with higher-risk prostate cancer. Whether the more extensive operation also improves cancer outcomes has been less clear. New long-term randomized data presented at the 2026 American...
NSCLC: FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
A refined dynamic prognostic model incorporating longitudinal measurable residual disease (MRD) assessments may improve prediction of progression-free survival and overall survival in patients with chronic lymphocytic leukemia (CLL) receiving limited-duration therapy. The findings, reported by...
Robert A. Kyle, MD, Myeloma Expert, Dies at 98
The International Myeloma Foundation (IMF) shared news of the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Prostate Cancer: Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Patients with nonmetastatic prostate cancer who consumed higher quantities of saturated fats, including animal fats, had a higher risk of all-cause mortality, including death from cardiovascular disease and other cancer, according to the results of a study published in JAMA Network Open. “Our...
Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer
Long-course chemoradiotherapy resulted in superior 12-month total mesorectal excision–free survival compared with short-course radiotherapy in the STAR-TREC trial. The interim analysis, led by Simon P. Bach, FRCS, and colleagues and published in The Lancet Oncology, included patients pursuing organ ...
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, HER2-negative...
Prostate Cancer: Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
A set of uncontrolled, modifiable cardiovascular risk factors may help identify a subgroup of patients with prostate cancer who could benefit from additional cardiovascular care, according to findings published in JACC: CardioOncology and presented at the ESC Congress 2026. “The major findings...
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Over the past 75 years, advances in the treatment of major blood cancers have saved more than 25 million years of life in the United States, according to results of an analysis led by researchers at Blood Cancer United and published by Chang et al in Blood Advances. But the gains have not reached...
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
Cervical cancer remains a preventable cause of morbidity and mortality, particularly among women who are not reached by screening programs. In a research letter published in JAMA Network Open, Sonawane et al emphasized the importance of identifying those who have never been screened and reported...
Dual Oral Regimen Shows Encouraging Activity in KRAS G12C–Mutated Metastatic Colorectal Cancer
The first clinical evaluation of the chemotherapy-free combination of ifebemtinib and garsorasib showed antitumor activity in patients with previously treated KRAS G12C–mutated metastatic colorectal cancer, although the improvement in objective response rate over garsorasib alone did not reach...
Hypofractionated Salvage Radiotherapy Evaluated After Prostatectomy for Biochemical Recurrence
According to interim results of the phase III SHARE trial reported by Song et al in the Journal of Clinical Oncology, hypofractionated salvage radiotherapy produced similar 4-year oncologic outcomes to conventional radiotherapy among patients with biochemical recurrence after radical prostatectomy, ...
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
The combination of the epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin and the PD-1 inhibitor pucotenlimab demonstrated antitumor activity in patients with recurrent or metastatic nasopharyngeal carcinoma previously treated with platinum-based...
ACS Publishes Report on Cancers in Asian American, Native Hawaiian, and Pacific Islander People
Cancer data for Asian American and Native Hawaiian and Pacific Islander (NHPI) people are usually combined, hiding vast differences in cancer risk. New disaggregated data analyzed by researchers at the American Cancer Society (ACS) show that Native Hawaiian women have a 27% higher breast cancer...
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
First-line treatment with the antibody-drug conjugate sacituzumab govitecan-hziy plus pembrolizumab led to a longer progression-free survival after next line of treatment—ie, progression-free survival–2 (PFS2)—than chemotherapy plus pembrolizumab in patients with previously untreated,...
Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma
The addition of spartalizumab to dabrafenib and trametinib demonstrated a long-term survival benefit in patients with BRAF V600–mutant metastatic melanoma, according to the final overall survival analysis from the phase III COMBI-I trial published in the Journal of Clinical Oncology. “[T]he...
Sociological Study Explores the Concept of ‘Temporal Misalignment’ Among Patients With Terminal Cancer
Scientists are making progress in developing new cancer treatments, but a patient’s experience with cancer is shaped by more than medicine. A new sociological study has found that conflicting medical, work, and family timelines compound inequality, draining resources and displacing goals for even...
Radiation to the Thymus in NSCLC Treatment May Increase Risk of Metastasis
Radiation to the thymus was found to be associated with worse outcomes in patients with non–small cell lung cancer (NSCLC), leading to an increased risk of metastasis, according to findings published in the Annals of Oncology. “The thymus is currently not routinely treated as an important organ...
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
For more than a decade, geriatric oncology has evolved from a niche discipline into an evidence-based component of high-quality cancer care. Landmark randomized trials, including the Geriatric Assessment for Patients 70 Years and Older Starting Cancer Treatment (GAP70+) trial,1 the Geriatric...
Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint
Investigators from Friends of Cancer Research (Friends) recently published two manuscripts supporting the use of circulating tumor DNA (ctDNA) as an early endpoint for regulatory decision-making. The first article, published by Andrews et al in the Journal of Liquid Biopsy, aggregated data from...
Additional Safety Analysis of DESTINY-Breast05: What Did It Show?
An additional safety analysis of the global phase III DESTINY-Breast05 trial evaluating the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has further established the pulmonary safety profile of T-DXd with radiotherapy, according to Michael Untch, MD, PhD, of Helios...
High-Dose Vitamin D3 Does Not Improve PFS in Metastatic Colorectal Cancer
Adding high-dose vitamin D3 to standard chemotherapy plus bevacizumab did not improve progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC), according to results from the phase III SOLARIS trial led by Kimmie Ng, MD, MPH, and colleagues and...
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
Today, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with essential thrombocythemia, making it the first new FDA-approved treatment for essential thrombocythemia in nearly 3 decades. Ropeginterferon alfa-2b-njft has been...
Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer
A tissue-free circulating tumor DNA (ctDNA) assay was strongly prognostic for recurrence in patients treated for triple-negative breast cancer and provided a lead time to recurrence comparable to that of a multivariant tumor-informed assay, according to findings from a prognostic study published by ...
cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions
A blood-based assay combining cell-free DNA (cfDNA) fragmentomics with droplet digital PCR–based methylation analysis improved detection of early-stage colorectal cancer (CRC) and precancerous lesions, according to findings presented at the 2026 ASCO Breakthrough meeting in Singapore. In this...
In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles
A comparative study of the cancer clinical trial portfolios supported by federal funding vs industry funding reveals they have distinct, interdependent roles in cancer research. The findings were published by Unger et al in JAMA Oncology. The analysis found that, whereas industry trials were more...
Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer
Researchers have reported that a chemotherapy-free combination of four targeted therapies showed encouraging results in patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option that may be more convenient for some...
Prostate Cancer: NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT
In the international phase III NRG-GU005 trial, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately hypofractionated intensity-modulated radiotherapy (IMRT) in patients with favorable intermediate-risk prostate cancer. However, Ellis et al reported in JAMA...
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
On August 26, the U.S. Food and Drug Administration (FDA) approved daraxonrasib (Rasonque), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy....
Dr. Gary R. Morrow, a Pioneer in Cancer Research, Dies at 82
Gary R. Morrow, PhD, MS, died on July 7, 2026, at age 82, from complications due to pneumonia and a 16-year history of prostate cancer, according to an obituary shared by his family. Over nearly 5 decades at the University of Rochester Wilmot Cancer Institute, Dr. Morrow brought in $100 million in ...
Research Finds Supercentenarians Have an Abundance of Cancer-Killing Immune Cells
The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. These cells multiply in a process called clonal expansion to help fight infection. In a study published by Hashimoto in Cell Reports, researchers...
ASCO Remembers Supportive Care and Symptom Management Pioneer Gary R. Morrow, PhD, MS
ASCO joins the oncology community in mourning the death of Gary R. Morrow, PhD, MS, who passed away on July 7, 2026; Dr. Morrow was 82. Dr. Morrow was a pioneer in the field of supportive care, and his research on the potentially debilitating side effects of cancer treatment, including nausea,...
FDA Approves Zanidatamab Combination Regimens for HER2-Positive Gastric, GEJ, or Esophageal Cancer
On August 25, 2026, the U.S. Food and Drug Administration (FDA) approved zanidatamab-hrii (Ziihera) for two indications, including: in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra), as first-line treatment for adults with HER2-positive...
The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care
To be a mid-career oncologist is to occupy an emotionally and physically taxing space within a trying clinical environment. We may be 10 years and beyond our post-training. We are no longer trainees who may be protected by institutional shields, nor are we established senior department heads with...
Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery
A short-term, intensive weight-loss program before surgery was feasible and produced meaningful weight loss in women with endometrial cancer and excess weight in the randomized ENDO-CARE trial. The intervention was also associated with fewer postoperative complications, although the study was not...
Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer
Metabolic abnormalities were frequently documented during the first year after men with prostate cancer began concurrent androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI), according to a large retrospective cohort study led by Amy L. Shaver, PhD, PharmD, MPH, and...
Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy
New results from the international, randomized, phase III OPTIMA trial indicate that select patients with clinically high-risk, estrogen receptor–positive, HER2-negative early breast cancer who have a low risk of recurrence based on tumor gene expression testing may be able to safely avoid...
Living Guideline Adds Repotrectinib and Zongertinib as Treatment Options for Advanced NSCLC With Driver Alterations
ASCO has issued a new update to its Living Guideline on therapy for stage IV non–small cell lung cancer (NSCLC) with driver alterations, including new recommendations for two therapies: repotrectinib, a ROS1 tyrosine kinase inhibitor (TKI), and zongertinib, a HER2-selective, EGFR-sparing TKI.1 The...
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
The U.S. Food and Drug Administration (FDA) has released a discussion paper regarding factors that go into the regulation of generative artificial intelligence (AI)–enabled medical devices and is asking for public feedback, focusing on areas such as risk assessment, premarket evaluation, and...
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
Merck and Moderna, Inc. have announced positive topline results from the phase III INTerpath-001 trial (ClinicalTrials.gov identifier NCT05933577) evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen...
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
Flight attendants and pilots had the highest and second-highest risk-adjusted percentages of deaths from radiation-related cancers, respectively, among more than 500 occupations in the United States, according to the results of a population-based analysis reported by Patel et al in a research...
